Please login to the form below

Not currently logged in
Email:
Password:

Celgene’s Abraxane receives FDA approval in lung cancer

Adds to current breast cancer indication

Celgene can now market its breast cancer drug Abraxane in the US for treatment of non-small cell lung cancer (NSCLC) after receiving an additional approval from the Food and Drug Administration (FDA).

Abraxane is already available to treat patients with metastatic breast cancer who have failed to respond to other treatments, but can now be used for the first-line treatment of locally advanced or metastatic NSCLC, in combination with carboplatin, in patients who are unable to undergo surgery or radiation therapy.

The approval opens up a new market for the drug, which achieved revenues of $168m during the first six months of 2012 in its current indication. Analysts have said its performance in lung cancer could add more than $100m to these annual sales.

Abraxane combines the chemotherapy paclitaxel with the protein albumin in order to improve the delivery of the active ingredient to cells.

In a phase III trial, Abraxane was able to reduce tumour size in 33 per cent of patients, while paclitaxel used without the albumin only managed to reduce tumour size in 25 per cent. Both arms of the trial studied the drug in combination with carboplatin.

Dr Mark Socinski, director of the lung cancer section in the division of heamatology/oncology at University of Pittsburgh, and lead investigator of the Abraxane trials, held the FDA approval as another step in fighting what is the leading cause of cancer death in the US.

“The FDA approval of Abraxane is exciting for healthcare professionals because it offers an important new treatment option for all types of non-small cell lung cancer patients, in an area that has seen few treatment advancements in recent years.”

Celgene has filed additional regulatory submissions in Japan, Australia and New Zealand, with decisions anticipated at some point during 2013.

The drug is also currently in various stages of investigation for the treatment of several other cancers, including pancreatic, metastatic melanoma, bladder, ovarian, and expanded applications for breast cancer.

15th October 2012

From: Sales, Marketing, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clinigen

Clinigen Global Access Programs specializes in the consultancy, development, management and implementation of access programs across the product lifecycle for...

Latest intelligence

Free White Paper: Customer Experience for Pharma
To learn why an effective customer experience strategy is vital for pharma, download our white paper “Customer experience for pharma” to learn more....
How ethical is your brand plan? Introducing the hEQ.
Assess your brand plan’s Healthcare Ethics Quotient and see how these questions can give your brand plan a new perspective and engage your internal teams and external customers....
solution_options.png
Why e-detailing must give options to healthcare professionals
We know, we know. You want to talk about your treatment right away, but this really is an essential step that will make your e-detailing even more credible....